medigraphic.com

2002, Número 1

<< Anterior Siguiente >>

Rev Fac Med UNAM 2002; 45 (1)


Cardiopatía isquémica. Hiperhomocisteinemia e infección

Carrillo ER, González SJA

Idioma: Español
Referencias bibliográficas: 62
Paginas: 17-21
Archivo PDF: 47.81 Kb.


RESUMEN

La hiperhomocisteinemia y las infecciones crónicas, principalmente por Chlamydia y citomegalovirus son factores importantes de riesgo para el desarrollo de aterosclerosis y cardiopatía isquémica.
Los pacientes con dichos factores de riesgo, así como la población general mayor de 65 años deben recibir un suplemento de ácido fólico en la dieta. En los portadores de cardiopatía isquémica debe practicarse un estrecho escrutinio para la búsqueda de infección por Chlamydia o citomegalovirus para prevenir accidentes agudos.
Igualmente debe buscarse y tratarse agresivamente la enfermedad parodontal.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wood D, de Bacher G, Faergeman O et al. Prevention of coronary Heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other societies coronary prevention. Eur Heart J 1998; 19: 1434-1503

  2. Wilson P, D´Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.

  3. Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.

  4. Arnesen E, Refsum H, Bonaa KH et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-709.

  5. Clarke R, Daly L, Robinson K et al. Hyper-homocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.

  6. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis: J Am Coll Cardiol 1996; 27: 517-527.

  7. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of atherosclerosis. Am J Pathol 1969; 56: 111-128.

  8. Refsum H, Ueland PM, Nygard O, et al. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.

  9. Chauveau P, Chadefaux B, Coude M, et al. Increased plasma homocysteine concentration in patients with chronic renal failure. Miner Electolyte Metab 1992; 18: 196-198.

  10. Arnadottir M, Hultberg G, Vladov V et al. Hyper-homocysteinemia in cyclosporine treated renal transplant recipients. Transplantation 1996; 61: 509-512.

  11. Bostom AG, Lahtrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to atherosclerotic outcomes. Kidney Int 1997; 52: 10-20.

  12. Fodinger M, Mannhalter C, Wolfl G et al. Mutation (677C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517-523.

  13. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: A common mutation in methyltetrahydrofolate reductase (letter). Nat Genet 1995; 10: 111-113.

  14. Bhagat K, Vallance P. Nitric oxide 9 years on J R Soc Med 1996; 89: 667-673.

  15. Chen P, Poddar R, Tipa E et al. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv. Enzyme Regul 1999; 39: 93-109.

  16. Harker LA, Slichter SJ, Scott CR et al. Homocysteinemia: Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-543.

  17. Wall RT, Harlan JM, Harker LA, et al. Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury. Thromb Res 1980; 18:113-121.

  18. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine induced vascular endothelial cell activator. J clin Invest 1968; 77: 1909-1916.

  19. Tawkol A, Omland T, Gerhard M et al. Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation 1997; 95: 1119-1121.

  20. Tsai JUC, Perrella MA, Yoshizumi M et al. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Nat Acad Sci USA 1994; 91: 6369-6373.

  21. Stambler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen J. Clin Invest 1993; 91: 308-318.

  22. Ridker PM, Hennekens CH, Selhub J et al. Interrelation of hyperhomocysteinemia, factor V Leiden, and risks of future venous thromboembolism. Circulation 1997; 95: 1777-1782.

  23. Ueland PM, Mansoor MA, Guttormsen AB, et al. Reduced, oxidized and protein-bound forms of homocysteine and other aminothiols in plasma comprise the redox thiol status a possible element of the extracellular antioxidant defense system. J Nutr 1996; 126(4 suppl): 1281S-1284S.

  24. Upchurch GR Jr, Welch GN, Fabian AJ et al. Homocysteine decreases bioavailable nitric oxide by a mechanism involving gluthatione peroxidase. J Biol Chem 1997; 272:17012-17017.

  25. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease: A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-1082.

  26. Boushey CJ, Beresford SA, Omenn GS et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.

  27. Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 concentrations: Risk factors for stroke, peripheral vascular disease and coronary artery disease. European COMAC Group. Circulation 1998; 97: 437-443.

  28. Folsom AR, Nieto FJ, McGovern PG et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-210.

  29. Brattstrom L, Israelsson B, Norrving B et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: Effects of pyridixone and folic acid treatment. Atherosclerosis 1990; 81: 51-60.

  30. den Heijer M, Rosendaal FR, Blom HJ et al. Hyperhomocysteinemia and venous thrombosis: A meta-analysis. Thromb Haemos 1998; 80: 874-877.

  31. Wilcken DE, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism 1983; 32: 363-370.

  32. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyperhomocysteinemia. Lancet 1998; 351: 263.

  33. Lobo A, Naso A, Arheart K et al. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Am J Cardiol 1999; 83: 821-825.

  34. Malinow MR, Bostom, AG, Krauss RM. Homocysteine, diet and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999, 99: 178-182.

  35. Jacques PF, Selhub J, Bostom AG et al. The effect of folic acid fortification on plasma folate levels and total homocysteine concentrations. N Engl J Med 1999; 340:1449-1454.

  36. Nappo F, De Rosa N, Marfella R et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281: 2113-2118.

  37. de Beer FC, Hind CR, Fox KM et al. Measurement of serum C reactive protein concentration in myocardial ischemia and infarction. Br Heart J 1982; 47: 239-243.

  38. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) investigators. Circulation 1999; 99: 1161-1164.

  39. Haverkate F, Thompson SG, Pyke SD et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-466.

  40. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999; 340: 115-126.

  41. Saikku P, Leionen M, Tenkanen L et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273-278.

  42. Saikku P, Mattila K, Nieminen MS et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1998; 2: 983-986.

  43. Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: Meta-analysis of 18 studies. BMJ 1998; 316: 1130-1132.

  44. Danesh J, collins R, Peto R. Chronic infections and coronary heart disease. Is there a link? Lancet 1997; 350: 430-436.

  45. Grattan MT, Moreno-Cabral CE, Starnes VA et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-3566.

  46. Kuo CC, Shor A, Campbell LA et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-849.

  47. Gaydos CA, Summergill JT, Sahney NN et al. Replication of Chlamydia pneumoniae in vitro in human macrophages endothelial cells and aortic artery smooth muscle cells. Infect Immun 1996; 64: 1614-1620.

  48. Kalman S, Mithcell W, Marathe R et al. Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat Genet 1999; 21: 385-389.

  49. Yang X, Galeano NF, Szabolcs M et al. Oxidized low density lipoproteins alter macrophage lipid uptake, apopotosis, viability and nitric oxide synthesis. J Nutr 1996; 126(4 suppl l) 1072S-1075S, 1996.

  50. Zhou J, Quyyumi AA, norman J et al. The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Am Coll Cardiol 1999; 33 (suppl A) 4A.

  51. Fryer RH, Schwobe EP, Woods ML et al. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Investig Med 1997; 45: 168-174.

  52. Speir E, Huang ES, Modali R et al. Interaction of human cytomegalovirus with p53: Possible role in coronary restenosis. Scand J Infect Dis suppl 1995; 99: 78-81.

  53. Steele RJ, Thompson AM, Hall PA et al. The p53 tumor suppressor gene, Br J Surg 1998; 85: 1460-1467.

  54. Meyer MW, Gong K, Herzberg MC. Streptococcus sanguis-induced platelet clotting in rabbits and hemodynamic and cardiopulmonary consequences. Infect Immun 1998; 66: 5906-5914.

  55. Libby P, Sukhove G, Lee RT et al. Cytokines regulate vascular function related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 12: 2-59, 1995.

  56. Anderson JL, Muhlestein JB, Carlquist J et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia Study. Circulation 1999; 99: 1540-1547.

  57. Minick CR, Fabricant CG, Fabricant J et al. Atherosclerosis induced by infection with a herpes virus. Am J Pathol 1979; 96: 673-706.

  58. Miyashite N, toyota E, Sawayama T et al. Association of chronic infection of Chlamydia pneumoniae and coronary heart disease in the Japanese. Intern Med 1998; 37: 913-916.

  59. Slavkin HC: Does the mouth put the heart at risk? Journal of the American Dental Association 1999; 139: 109-113.

  60. DeStefano F, Anda RF, Kahn HS et al. Dental disease and risk of coronary heart disease and mortality. BMJ 1993; 306-688-691.

  61. Beck J, Garcia R, heiss G et al. periodontal disease and cardiovascular disease. J. Periodontol 1996; 67(10supl): 1123-1137.

  62. Mendez MV, Scott T, LaMorte W et al. An association between periodontal disease and peripheral vascular disease. Am J Surg 1998; 176: 153-157.




2020     |     www.medigraphic.com